Conformis, Inc., a medical technology company, develops, manufactures, and sells patient-specific products and instrumentation. The company offers personalized knee replacement products, including iUni, iDuo, a custom-made partial knee replacement option for either unicompartmental or bicompartmental osteoarthritis of the knee; iTotal CR, a cruciate retaining total knee replacement product; iTotal PS, a posterior stabilized knee replacement product, as well as provides iTotal Identity and Identity Imprint knee replacement products. It also provides Conformis Hip System and Cordera hip replacement, which are hip replacement products; and iJigs, a personalized single-use patient-specific instrumentation. The company markets and sells its products to orthopedic surgeons, hospitals, and other medical facilities through sales force, independent sales representatives, and distributors in the United States, Germany, the United Kingdom, Austria, Ireland, Switzerland, Spain, Portugal, the Netherlands, Belgium, the Dutch Antilles, Suriname, Australia, the United Arab Emirates, the Sultanate of Oman, Italy, Poland, and other markets. Conformis, Inc. was incorporated in 2004 and is headquartered in Billerica, Massachusetts.
Conformis Stock Performance
CFMS opened at $0.27 on Wednesday. The company has a fifty day moving average of $0.32 and a 200 day moving average of $0.49. The stock has a market capitalization of $50.94 million, a price-to-earnings ratio of -6.87 and a beta of 1.25. The company has a debt-to-equity ratio of 0.24, a quick ratio of 5.87 and a current ratio of 6.84. Conformis has a fifty-two week low of $0.25 and a fifty-two week high of $1.96.
Conformis (NASDAQ:CFMS - Get Rating) last posted its earnings results on Monday, August 8th. The medical instruments supplier reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.01). Conformis had a negative net margin of 6.83% and a negative return on equity of 6.50%. During the same quarter last year, the firm earned $0.21 earnings per share. As a group, sell-side analysts forecast that Conformis will post -0.31 earnings per share for the current fiscal year.
Analysts Set New Price Targets
Separately, StockNews.com began coverage on Conformis in a research note on Tuesday. They issued a "hold" rating for the company.